NEW YORK (GenomeWeb News) – CombiMatrix today said that Pathology, Inc. will market and distribute its chromosomal microarray tests for "products of conception" testing in designated areas in the US.
Products of conception testing enables physicians to better determine if there is a genetic cause behind a miscarriage or multiple events, said Irvine, Calif.-based CombiMatrix.
Under terms of the agreement, Pathology will market and distribute the tests in California and Nevada, as well as the Chicago and St. Louis metropolitan areas. The firms will participate in sales force training and market development activities, and Torrance, Calif.-based Pathology will need to generate a minimum amount of tests each quarter to maintain its exclusive rights in the designated markets.
Further terms of the agreement were not disclosed.
CombiMatrix President and CEO Judd Jessup said that the agreement with Pathology will enable the firm to expand its geographical reach and access to the women's health market.